New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 22, 2013
20:25 EDTMOLX, MOLX, CMC, CMC, UNF, UNF, PB, PB, ROL, ROL, LCC, LCC, OC, OC, TUP, TUP, NDAQ, NDAQ, OCR, OCR, MDCO, MDCONotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Molex (MOLX), consensus 37c; Omnicare (OCR), consensus 90c; Nasdaq OMX (NDAQ), consensus 62c; Tupperware (TUP), consensus $1.03; Owens Corning (OC), consensus 65c; US Airways (LCC), consensus $1.12; Rollins (ROL), consensus 24c; Prosperity Bancshares (PB), consensus 90c; UniFirst (UNF), consensus $1.40; Commercial Metals (CMC), consensus 17c; The Medicines Company (MDCO), consensus 21c.
News For MOLX;OCR;NDAQ;TUP;OC;LCC;ROL;PB;UNF;CMC;MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
10:00 EDTTUPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:18 EDTTUPTupperware Brands downgraded at B. Riley
As previously reported, B. Riley downgraded Tupperware Brands to Neutral from Buy. The firm believes Street expectations for 14% local currency EPS growth is too optimistic and expects estimates to move lower as the U.S. dollar continues to strengthen. B. Riley expects 2015 guidance of $5.00 when it reports in late January vs. consensus of $5.47 Price target lowered to $72 from $83.
06:26 EDTTUPTupperware Brands downgraded to Neutral from Buy at B. Riley
Subscribe for More Information
November 24, 2014
10:24 EDTOCRHigh option volume stocks
High option volume stocks: TIVO TIF ASHR OCR TGP JEC CEQP UTX PWRD IMMU
08:31 EDTOCROmnicare, McKesson expand distribution agreement
Omnicare (OCR) and McKesson Corporation (MCK) announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals. The new five year agreement, which extends through December 2019, creates efficiencies for both companies by leveraging the strength of Omnicare as the nation’s largest institutional pharmacy and a leading specialty pharmaceutical services provider and McKesson as a global leader in pharmaceutical sourcing and supply chain management. Omnicare noted that it believes the benefits of its new sourcing strategy will be a key driver in enabling it to generate a low double-digit adjusted cash EPS growth rate in 2015.
November 20, 2014
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:41 EDTMDCOThe Medicines Co. upgraded at Credit Suisse
Subscribe for More Information
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 19, 2014
07:47 EDTNDAQKeefe Bruyette to hold a conference
Securities Brokerage & Market Structure Conference is being held in New York on November 19 with webcasted company presentations to begin at 7:45 am. Webcast Link
November 18, 2014
11:36 EDTTUPTupperware Brands sees local currency sales in 2015 up 4%-6%
Comments from slide presentation.
11:15 EDTTUPTupperware Brands backs FY14 EPS view $5.21-$5.26, consensus $5.25
Subscribe for More Information
11:13 EDTTUPTupperware Brands backs Q4 earnings view $1.55-$1.60, consensus $1.57
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information
November 12, 2014
08:19 EDTUNFJPMorgan to hold a conference
Subscribe for More Information
08:13 EDTNDAQBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use